Leap Therapeutics Trading Down 4.3 percent - MarketBeat
| LPTX Stock | USD 3.22 0.34 11.81% |
Slightly above 55% of Leap Therapeutics' investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Leap Therapeutics suggests that some traders are interested. Leap Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Leap Therapeutics' earnings reports, geopolitical events, and overall market trends.
Leap |
Leap Therapeutics Trading Down 4.3 MarketBeat
Read at news.google.com
 |
Leap Therapeutics Fundamental Analysis
We analyze Leap Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Leap Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Leap Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash Per Share
Cash Per Share Comparative Analysis
Leap Therapeutics is currently under evaluation in cash per share category among its peers. Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Leap Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Leap Therapeutics stock to make a market-neutral strategy. Peer analysis of Leap Therapeutics could also be used in its relative valuation, which is a method of valuing Leap Therapeutics by comparing valuation metrics with similar companies.
Peers
Leap Therapeutics Related Equities
| ABOS | Acumen Pharmaceuticals | 7.56 | ||||
| PDSB | PDS Biotechnology | 6.13 | ||||
| HEPA | Hepion Pharmaceuticals | 4.26 | ||||
| INZY | Inozyme Pharma | 2.89 | ||||
| XFOR | X4 Pharmaceuticals | 2.74 | ||||
| TERN | Terns Pharmaceuticals | 2.35 | ||||
| DAWN | Day One | 0.32 | ||||
| MREO | Mereo BioPharma | 0.57 | ||||
| ELEV | Elevation Oncology | 1.75 | ||||
| HOOK | Hookipa Pharma | 2.99 |
Additional Tools for Leap Stock Analysis
When running Leap Therapeutics' price analysis, check to measure Leap Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Leap Therapeutics is operating at the current time. Most of Leap Therapeutics' value examination focuses on studying past and present price action to predict the probability of Leap Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Leap Therapeutics' price. Additionally, you may evaluate how the addition of Leap Therapeutics to your portfolios can decrease your overall portfolio volatility.